# Trade Mark Journal No.2025/038 19 September 2025

## WO0000001873907 (5)

Office of origin: United States of America

Date of International Registration:22 July 2025
Date of designation in the UK: 22 July 2025

International priority date claimed: 6 February 2025 (United States of America) (99031152)

Class 5
  Pharmaceuticals and medicines for the treatment of cystic fibrosis, pain, sickle cell disease, beta thalassemia, muscular dystrophy, diabetes, respiratory diseases, liver disease, kidney disease, alpha-1 antitrypsin deficiency and APOL1-mediated kidney disease.

Vertex Pharmaceuticals Incorporated

Representative: Sarah Anne Keefe Womble Bond Dickinson (US) LLP, 470 Atlantic Avenue, Suite 600, Boston MA 02210, UNITED STATES OF AMERICA